Annual Drug Patent Expirations for ORILISSA
Orilissa is a drug marketed by Abbvie Inc and is included in one NDA. It is available from one supplier. There are six patents protecting this drug.
Drug patent litigation for ORILISSA.
This drug has thirty-nine patent family members in twenty-four countries.
The generic ingredient in ORILISSA is elagolix sodium. One supplier is listed for this compound. Additional details are available on the elagolix sodium profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
